{"metadata": {"source": "pubchem", "title": "Fentanyl | C22H28N2O | CID 3345 - PubChem", "description": "Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/3345", "drug": "Fentanyl", "cid": 3345, "char_count": 196495, "word_count": 26843, "doc_id": "doc_16", "num_chunks": 282, "chunk_id": "16::chunk_22", "document_index": 16, "latency_s": 1.657663699996192, "prompt_toks": 49722, "completion_toks": 89, "relevance_score": 0.0527164}, "content": "Drug: Fentanyl | cid: 3345\nSource: pubchem | Source description: Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    FDA Label\n\nEffentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. , , BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. , , Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. ,\n\n7.2 Drug Classes\n\nBreast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Anesthetics, Intravenous; Opiates\n\n7.3 Drug Transformations\n\nFentanyl has known transformation products that include Norfentanyl.\n\nS66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448\n\n7.4 FDA Medication Guides\n\n1 of 7\n\nView All\n\nDrug\n\nActive Ingredient\n\n\n                    Context: \n                    This excerpt provides detailed information regarding the FDA-approved label for Effentora, a fentanyl-based medication used to treat breakthrough cancer pain in opioid-tolerant adults, including its indications, drug classes, known transformation product Norfentanyl, and related medication guides. It is relevant to the comprehensive chemical and pharmacological data on fentanyl presented in the full document, highlighting clinical usage, drug transformations, and regulatory aspects essential for research and medical reference.\n                "}
{"metadata": {"source": "pubchem", "title": "Fentanyl | C22H28N2O | CID 3345 - PubChem", "description": "Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/3345", "drug": "Fentanyl", "cid": 3345, "char_count": 196495, "word_count": 26843, "doc_id": "doc_16", "num_chunks": 282, "chunk_id": "16::chunk_22", "document_index": 16, "latency_s": 1.657663699996192, "prompt_toks": 49722, "completion_toks": 89, "relevance_score": 0.0527164}, "content": "Drug: Fentanyl | cid: 3345\nSource: pubchem | Source description: Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    FDA Label\n\nEffentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. , , BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. , , Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. ,\n\n7.2 Drug Classes\n\nBreast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Anesthetics, Intravenous; Opiates\n\n7.3 Drug Transformations\n\nFentanyl has known transformation products that include Norfentanyl.\n\nS66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448\n\n7.4 FDA Medication Guides\n\n1 of 7\n\nView All\n\nDrug\n\nActive Ingredient\n\n\n                    Context: \n                    This excerpt provides detailed information regarding the FDA-approved label for Effentora, a fentanyl-based medication used to treat breakthrough cancer pain in opioid-tolerant adults, including its indications, drug classes, known transformation product Norfentanyl, and related medication guides. It is relevant to the comprehensive chemical and pharmacological data on fentanyl presented in the full document, highlighting clinical usage, drug transformations, and regulatory aspects essential for research and medical reference.\n                "}
{"metadata": {"source": "pubchem", "title": "Fentanyl | C22H28N2O | CID 3345 - PubChem", "description": "Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/3345", "drug": "Fentanyl", "cid": 3345, "char_count": 196495, "word_count": 26843, "doc_id": "doc_16", "num_chunks": 282, "chunk_id": "16::chunk_24", "document_index": 16, "latency_s": 1.0777218000002904, "prompt_toks": 49797, "completion_toks": 95, "relevance_score": 0.049681153}, "content": "Drug: Fentanyl | cid: 3345\nSource: pubchem | Source description: Fentanyl | C22H28N2O | CID 3345 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Company\n\nJANSSEN PHARMS\n\nDate\n\n3/4/21\n\n7.5 WHO Essential Medicines\n\nDrug\n\nDrug Classes\n\nFormulation\n\nIndication\n\nDrug\n\nFentanyl\n\nDrug Classes\n\nOpioid analgesics\n\nFormulation\n\n(1) Local - Topical - Transdermal patch: 12 Âµg/hour; 25 Âµg/hour; 50 Âµg/hour; 75 Âµg/hour; 100 Âµg/hour; (2) Oral - Solid: 100 to 800 Âµg sub-lingual tablet (as citrate); 200 to 1600 Âµg lozenge (as citrate); (3) Oral - Other: 200 to 1200 Âµg buccal film (as citrate)\n\nIndication\n\n(1) Chronic cancer pain; (2) Other specified chronic cancer related pain\n\n7.6 FDA Approved Drugs\n\n7.7 FDA Orange Book\n\n7.8 FDA National Drug Code Directory\n\n7.9 FDA Green Book\n\n7.10 Drug Labels\n\nDrug and label\n\nActive ingredient and drug\n\n7.11 Clinical Trials\n\n7.11.1 ClinicalTrials.gov\n\n7.11.2 EU Clinical Trials Register\n\n7.11.3 NIPH Clinical Trials Search of Japan\n\n7.12 DEA Drug and Chemical Information\n\nFentanyl\n\n(Trade names:Actiq®, Fentora™, Duragesic®)\n\n7.12.1 DEA Controlled Substances\n\n1 of 3\n\nSubstance\n\nFentanyl\n\n\n                    Context: \n                    This chunk presents detailed information on Janssen Pharmaceutics' fentanyl product formulations, approval dates, and regulatory classifications, including WHO essential medicine status, FDA drug listings, and controlled substance scheduling. It is relevant for comprehensive drug identification, regulatory status, and formulation data within the full chemical profile of fentanyl, aiding in search retrieval of approved medical uses, formulations, and legal classifications. Key details include dosage forms, indications, and regulatory identifiers, supporting drug-specific queries.\n                "}
